LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Inclusion Criteria: 1. Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information. 2. All ages allowed 3. Suspected or confirmed disease (must meet one of the criteria below): 1. Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis) OR 2. Suspected lipomatous mass concerning for ALT or WDLS with planned surgery OR 3. Confirmed bone or soft tissue sarcoma meeting one of the criteria below: * Non-metastatic/Resectable sarcoma with either planned or currently receiving therapy * Metastatic or unresectable sarcoma, with planned or currently receiving therapy * Non-metastatic sarcoma under surveillance with no more than 1 year from completion of therapy Exclusion Criteria: * none